✦ LIBER ✦

Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in

✍ Scribed by Goede, V; Fischer, K; Busch, R; Jaeger, U; Dilhuydy, M-S; Wickham, N; De Guibert, S; Ritgen, M; Langerak, A W; Bieska, G; Engelke, A; Humphrey, K; Wenger, M; Hallek, M

Book ID: 118048089
Publisher: Nature Publishing Group
Year: 2012
Tongue: English
Weight: 335 KB
Volume: 27
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2012.252

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Potential Cost-Effectiveness of Obin

The Potential Cost-Effectiveness of Obinutuzumab (Ga101) in Combination with Chlorambucil in Chronic Lymphocytic Leukemia

✍ Walzer, S.; Becker, U.; Samanta, K.; Wiesner, C.; Mueller, E. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Chemoimmunotherapy may overcome the adve

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

✍ Apostolia-Maria Tsimberidou; Constantine Tam; Lynne V. Abruzzo; Susan O'Brien; W 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB

PCN67 COST UTILITY ANALYSIS OF ALEMTUZUM

PCN67 COST UTILITY ANALYSIS OF ALEMTUZUMAB COMPARED TO CHLORAMBUCIL IN UNTREATED PATIENTS WITH HIGH-RISK (17P-) CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM

✍ AC Lloyd; A Valderrama; J Ferguson; L Gilmour; F Ravndal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

5.23 Phase 2 Study of Navitoclax (ABT-26

5.23 Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results

✍ John F. Seymour; Andrew W. Roberts; Dennis A. Carney; Martin J.S. Dyer; Thomas J 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 71 KB

5.40 Rituximab Maintenance in Patients w

5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC)

✍ Francesc Bosch; Pau Abrisqueta; Neus Villamor; María José Terol; Eva González-Ba 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 250 KB

Alemtuzumab by continuous intravenous in

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

✍ Stefan Faderl; Alessandra Ferrajoli; William Wierda; Susan O'Brien; Susan Lerner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 2 views